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Abstract 
         Introduction:  Ketorolac  tromethamine  is  a  potent  injectable  non-steroidal  anti-
inflammatory  drug  (NSAID).  Ketorolac  provides  successful  analgesia  after  intrathecal  or 
epidural  injection.        It  is  frequently  used  to  manage  post-operative  pain,  cancer  pain,  and 
arthritis  either  intrathecally,  or  intramuscular.  However,  its  long  term  administration  could 
induce renal toxicity and/or gastro-intestinal ulceration.  
         Aim of the study: The aim of this study was to assess the analgesic potency of ketorolac 
after intrathecal injection. Also, we aimed to study the histological effect of ketorolac on the 
spinal cord and the duodenum after treatment in an animal model. 
         Methods: 40 adult male albino rats, weighing 250-350 gm, were used and divided into 4 
groups, 10 rats each. Group S (control) received 10μl normal saline intrathecally, group K50 
received  50μg  ketorolac  intrathecally,  group  K50  +  omeprazole  (proton  pump  inhibitor) 
received 50μg ketorolac intrathecally plus 0.2 mg omeprazole orally, and finally, group K100 
received 100μg ketorolac intrathecally. All animals were treated for four successive days. 
         Result: The rat tail flick latency was longer in K50, K50 + omeprazole, and K100 groups 
when  compared  to  normal  control  (P  =  0.002).  Also,  the  hind-paw  withdrawal  latency  was 
longer in treated groups when compared to those of the control group (P = 0.0001). Moreover, 
K50  group  showed  decreased  phase  II  response  by  61%,  K50  +  omeprazole  group  showed 
decreased phase II by 62%, while K100 group showed decreased it by 76%.  
Histological examination revealed  no changes in  the spinal  cord of all  treated animals.  Also, 
examination  of  the  duodenum  showed  normal  duodenal  mucosa  in  group  K50  and  those  of 
group K50 + omeprazole. On the other hand, cellular infiltration as well as destruction of the 
mucous acini have been noticed in the duodenum of K100 group. 
         Conclusion: Ketorolac could be a good alternative drug used intrathecally to manage pain. 
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Introduction 
 
         The study of intrathecal application of 
drugs to manage pain is important for two 
reasons.  First,  it  is  directly  relevant  to 
anesthesia  practice  in  that  the  intrathecal 
space is often instrumented as part of peri-
operative,  or  chronic  pain  care.  Second,  it 
provides  important  information  regarding 
mechanisms of analgesic action and of pain 
transmission,  which  could  guide 
pharmaceutical  development  of  both 
intrathecal and systemic drug development. 
A  good  example  of  these  rationales  is 
examination  of  cyclooxygenase  (COX) 
enzyme  expression  and  inhibition  in  the 
spinal cord  as  it  relates  to  pain  treatment. 
COX is expressed in the normal spinal cord 
in  small  amounts,  both  isoforms  COX-1 
and  COX-2.  Brocks  and,  Jamali  (1992). 
Indeed, the constitutive presence of COX-2 
in  the  spinal  cord  has  been  suggested  to 
underlie the early analgesic effect of COX 
inhibitors  after  surgery  or  other  peripheral 
injury and at times before peripheral COX-
2  expression  is  increased.  After  peripheral 
injury, spinal COX-2  expression is  greatly 
enhanced,  leading  to  increased  spinal 
release  of  prostaglandins  with  resultant 
increased  substance-P  release  and  central 
sensitization.  Gillis  and  Brogden.  (1997) 
For this reason, spinally administered COX 
inhibitors  produce  analgesia  after  injury 
(Conklin and Eisenach, 2003).  
         Ketorolac  tromethamine  is  an 
injectable  non-steroidal  anti-inflammatory 
drug  (NSAID)  approved  in  1990  for 
treating  post-operative  pain.  Ketorolac  is 
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frequently  used  to  manage  postoperative 
pain, renal colic, arthritis, and cancer pain 
either  intrathecally  or  intramuscular.  
Ketorolac has also been reported to provide 
successful analgesia  when  injected  through 
epidural  way  (Gillis  and  Brogden  1997) 
.Ketorolac,  a  peripherally  acting  drug,  has 
become a popular alternative to opoids for 
postoperative  analgesia,  because  of  its 
minimal central nervous system side effects 
specifically  respiratory  depression, 
sedation, or nausea and vomiting (Miranda 
et  al.,  1993).As  a  NSAID  drug,  ketorolac 
inhibits  platelet  aggregation,  and  its  long 
term  administration  could  induce  renal 
toxicity and/or gastro-intestinal ulceration.  
         Ketorolac  has  also  been  reported  to 
provide  successful  analgesia  when  injected 
by  intrathecal  and  epidural  way  in  animal 
models. To consider the possible reaction of 
intrathecal ketorolac in man, it is necessary 
to  establish  the  pharmacokinetic  and  the 
effects  upon  spinal  cord  after  intrathecal 
delivery  in  well  defined  experiment. 
Analgesic  effect  of  intrathecal 
administration  of  ketorolac  has  been 
investigated in mouse, rat, and dog models 
before its recent used in man. (Eisenach et 
al., 2002). 
 
Material and Methods 
 
1- Pharmacological study: 
         Forty adult male albino rats weighing 
250 – 350 g were subjected to the present 
study.  Animals  were  housed  with  free 
access  to  food  and  water,  and  maintained 
on  a  12  hour  light/dark  cycle.  Rats  were 
anesthetized  with  2%  halothane  in 
oxygen/air, and then polyethylene catheters 
(Gauge 27)  were inserted through a small 
incision in the atlanto-occipital membrane, 
and then passed 8cm caudally to the level 
of  the  lumber  enlargement.  To  confirm 
correct placement of the catheter we inject 
10μl  of  2%  lidocaine  followed  by  10μl 
0.9%  saline  to  flush  the  catheter 
(Yamamoto and, Yaksh. 1992). All animals 
were developed bilateral motor block of the 
hind  limbs  within  30  seconds  that  lasted 
within two days.    
         Animals were divided into 4 groups, 
10  rats  each.  First,  group  S  (control), 
injected  with  10μl  sterile  saline  0.9% 
intrathecally.  Second,  group  K50,  where 
animals  were  injected  intrathecally  with 
50μg  ketorolac  dissolved  in  10ul  normal 
saline.  Third,  group  K50  +  Omeperazole, 
where animals received 0.2mg omeperazole 
(proton  pump  inhibitor)  orally  one  hour 
before  intrathecal  injected  with  50μg 
ketorolac  dissolved  in 10μl  normal saline. 
Lastly,  group  K100,  where  animals  were 
injected intrathecally with 100μg ketorolac 
dissolved in 10μl normal saline. All doses 
were given daily for four successive days. 
At  the  fourth  day,  15  minutes  after 
intrathecal  injection  rat  flick  test,  and  hot 
plate test were assessed.   
 
A- Rat flick test: 
         The  nociceptive  threshold  was 
measured  by  latency  of  the  tail  flick 
responses elicited by radiant heat applied to 
the  lower  third  of  the  tail.  The  mean  tail 
flick  latency  (TFL)  of  three  measurements 
was taken as the basal threshold. Adjust the 
amplitude of radiant heat, so that the basal 
TFL  was  within  4-6  seconds  (Sec.).  The 
TFL  taken  at  15  minutes  intervals  after 
intrathecal  injection  was  expressed  as  the 
percentage  change  from  basal  tail  flick 
latency,  with  cut-off  limit  of  150%  above 
baseline to avoid unnecessary skin damage. 
In the present study the cut-off time was 14 
Sec. 
 
B- Hot plate test:  
         The  hind-paw  withdrawal  latency 
(HWL) was measured by the hot plate test. 
The HWL to noxious heat stimulation was 
tested  by  the  hot  plate  maintained  at 
temperature of 52°C. The time of the hind-
paw  withdrawal  was  measured  in  seconds 
to  be  referred  as  HWL  to  thermal 
stimulation.  The  HWL  was  measured 
before  intrathecal  injection  of  ketorolac  as 
the basal threshold 4-6 Sec. A cut-off  limit 
of  15  Sec.  was  set  up  to  avoid  tissue 
damage (Sun  et al., 2003).  
C- Formalin test: 
         The  formalin  modified  test  ( 
Malmberg,  and  Yaksh  1993).  was 
performed  15  minutes  after  the  last 
intrathecal injection. Rats were anesthetized 
with 2% halothane in oxygen/air, and then 
50ul  of  5%  formalin  was  injected 
subcutaneously  into  the  dorsal  surface  of 
the  right  hind-paw  with  26-gauge  needle. Intrathecal Ketorolac Injection in Albino Rats;………….  
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After  formalin  injection,  flinches  were 
counted for 1 minute interval at 1 minute, 5 
minutes and 10 minutes, and then every 10 
minutes  for  1  hour.  Two  phases  of 
spontaneous  flinching  behavior  observed. 
Phase I;  begins immediately  after  formalin 
injection,  and  lasts  to  the  second 
observation  interval  (5  minutes).  Phase  II; 
begins at the 10
th minutes and lasts through 
60  minutes.  Thus,  the  mean  of  the  first  2 
measurements  (at  one  and  five  minutes) 
was the phase I value, and the mean of the 
remaining  measurements  was  phase  II 
value. 
2- Histological study: 
At  the  fifth  day,  rats  were  sacrificed, 
bilateral  laminecomty  was  performed,  and 
spinal  cord  with  the  companying  catheter 
tips  located  at  the  lumber  enlargements 
were  removed  from  the  vertebral  canals. 
Laparotomy  was  performed;  part  of  the 
duodenum  was  removed.  Samples  were 
fixed  in  10%  formalin  buffered  saline, 
embedded in paraffin, and  cut out into 6μm 
thick  sections.  Duodenal  Sections  were 
stained  with  hematoxylin  and  eosin  stain, 
and spinal cord  sections were stained  with 
Toluidin  blue  to  demonstrate  nerve  cells, 
with Nissl granules (Drury and Wallington 
1980). 
 
Statistical analysis: 
         Data  from  nociceptive  tests  were 
presented  as  mean  ±  SD.  Differences 
between  groups  were  determined  by 
analysis of variance (ANOVA). P<0.05 was 
considered as significant difference. 
 
Result 
 
Pharmacological study: 
A-  As  regard  to  the  effect  of  intrathecal 
administration  of  ketorolac  on  rat  tail 
flick  responses;  the  mean  TFL  was 
longer in groups K50, K50+ omeprazol, 
and K100 than control group (S group), 
as shown in table-1. 
B-  As regard to the hot plate test, the mean 
value  of  HWL  was  longer  in  groups 
K50, K50+ omeprazol, and K100 than 
control  group  (S  group),  as  shown  in 
table-2.  
C-  The effect of intrathecal administration 
of  ketorolac  on  formalin  test  is 
represented  in  table-3.  As  regard  to 
phase  I,  there  were  non  significant 
difference  between  ketorolac  injected 
groups and control (S) group, whereas 
there  were  significant  reduction  in  the 
number  of  flinching  in  ketorolac 
injected groups than in S group. 
 
Histological study:  
-  There  were  no  microscopic  changes 
noticed  in  the  spinal  cord  in  treated 
groups  [fig.  2(A&B)  and  3]  compared 
to that of the control [fig. 1(A&B)] 
-  Also;  microscopic  examination  of  the 
duodenum  of  control  group  showed 
normal  intestinal  mucosa,  where  the 
villi  are  lined  with  intact  columnar 
cells,  as  well  as  normal  submucosal 
mucous acini (fig. 4 & 5).    
-  Additionally;  duodenal  mucosa  of  the 
treated  groups  (K50  and  K50+ 
omeperazol)  showed  normal  structure 
(fig.  6).  On  the  other  hand,    the 
duodenal  mucosa  of    group  K100 
showed  cellular  infiltration  of  the 
duodenal villi, but with normal mucosal 
epithelium  (fig.  7);  and  destruction  of 
the submucosal mucous acini (fig. 8). 
Table (1): Tail flick latency 
 
 
Control 
Group  K50 Group 
Group K50+ 
omeperazol  K100 Group  F  p 
Means (S)  4.9  9.7*  9.3*  10.9*  68.64  0.002 
SD  0.7379  ±1.1595  ±1.595  0.9     
 Mean= Mean value of TFL in seconds 
S= Seconds 
*P< 0.05= significant 
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Table (2): Hot Plate test 
 
 
Control 
Group  K50 Group 
Group K50+ 
omeperazol  K100 Group  F  p 
Means (S)  4.7*  9.5*  9.3*  11*  76.32  0.0001 
SD  0.8233    1.0801  0.9487  1.0541     
Mean =Mean value of HWL in seconds 
 
Table (3): Formalin test 
 
Number of flinching 
  
Control 
Group  K50 Group 
Group K50+ 
omeperazol  K100 Group  F  p 
 Phase I 
  
Mean  16.7  15.3  15.00  13.9  94.4 
 
0.8 
  SD  2.9078  0.9487  0.8165  0.994 
Phase II  
  
Mean  19.3  *7.90  *7.500  *4.8  43.68 
 
0.0002 
  SD  0.9487  0.9487  1.0801  0.788 
 %of decreased 
Phase II responses 
  
  
  
  
61% 
 
62% 
 
76% 
 
 
 
0.002 
 
Mean= Mean value of numbers of flinching 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
(Fig.1; A&B): Normal nerve cells of the spinal cord of control rat, showing Nissl granules. 
              Toluidin blue    X250 (A)       X400(B) 
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(Fig. 2; A&B): Section of the spinal cord of ketorolac injected rat (group K50) showing 
normal nerve cells.           Toluidin blue   X250 (A)   X400 (B) 
                                                                                    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 (Fig. 3): Section of the spinal cord of ketorolac injected rat (group K100) showing normal 
nerve cells.               Toluidin blue     X400 Tarek A. Atia et al 
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 (Fig.  4):  Section  of  the  duodenum    of  control    rat  showing  normal  villi  with  normal 
immune cell content.                 H&E    X400 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Fig. 5): Section of the duodenum submucosa of control rat showing normal mucous acini.
                     H&E    X400 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 (Fig.  6):  Section  of  the  duodenum  of  ketorolac  injected  rat  (group  K50  +  omeprazol)  
showing normal villi and normal immune cell infiltration.       H&E X400 
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(Fig. 7): Section of the duodenum of ketorolac injected rat (group K100), where the villi  
show marked cellular infiltration, but with intact epithelium.                           H&E    X400
     
                                                                                            
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 (Fig.8)  :  Section  of  the  duodenum  of  ketorolac  injected  rat  (group  K100)  showing 
destruction of mucous  acini associated with immune cell infiltration.    
                                                                                                                          H&E X400 
                                                                                                                  
Discussion: 
 
         Many  different  NSAIDs  have  been 
evaluated  after  central  administration  in 
animal pain models. Rats, mice, and rabbits 
have been the most commonly used species 
in  experiments  testing  acute  pain  due  to 
mechanical  and  thermal  stimuli  or  pain 
associated  with  inflammation.  Drugs  that 
have  been  studied  include  indomethacin, 
flurbiprofen,  acetaminophen,  ketorolac, 
ibuprofen,  diclofenac,  ketoprofen,  and 
others  (Malmberg  and  Yaksh,  1993).  The 
route  of  administration  varies  from 
epidural, spinal, or intracerebroventricular. 
These  drugs  have  varying  degrees  of 
analgesic potency that is not related solely 
to  their  ability  to  inhibit  cyclooxygenase 
(McCormack,  1994).  Therefore,  other 
mechanisms  must  play  a  role  in  the 
analgesic  effects  of  centrally  administered 
NSAIDs.  Tarek A. Atia et al 
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         Ketorolac has a potent inhibitor effect 
upon  cyclooxygenase  (COX)  isozymes 
(Brocks and Jamali 1992). Several authors 
have  reported  the  analgesic  effect  of 
intrathecal  ketorolac  in  managing  pain  in 
man. However, a single intrathecal dose of 
ketorolac  can  produce  analgesia  in  rats. 
Although  repeated  doses  of  some  drugs 
such  as  neostigmine,  opiates,  or  A1 
receptors  agonist  (R-PIA)  have  not 
pathological reaction; a single injection of 
other  drugs  such  as  somatostatin  or 
dynorphin  induces  irreversible  motor 
dysfunction  and  histological  changes  in 
spinal cord (Korkmaz et al.,2004) 
         In  the  rat,  it  has  been  shown  that 
intrathecal ketorolac injection of  (10
 µg/10 
µl)  bolus  can  produce  a  potent  analgesia. 
However,  the  maximum  dose  that  can  be 
delivered without any spinal toxicology
 was 
(50 µg/10 µl) (Malmberg
 and Yaksh, 1993). 
Intrathecal  injection  of  ketorolac  is 
routinely  administered  once  in  therapeutic 
dose  for  treating  postoperative  pain,  or 
frequently  (but  not  daily)  for  managing 
chronic pain. In the current study we have 
used  the  maximum  doses  (50  µg/10  µl) 
with  and  without  proton  pump  inhibitor, 
and another extra dose (100 µg/10 µl)  of 
ketorolac for four successive days to detect 
the  pharmacological  as  well  as  the 
morphological changes.  
         Ketorolac  prevented  nociceptive  pain 
with limited effect on phase I responses in 
the formalin test contrary to its strong effect 
on  phase  II  responses.  50μg  ketorolac 
decreased phase II responses by about 61%, 
50μg  ketorolac  with  omeperazol  decreased 
phase II responses by 62%, whereas 100μg 
ketorolac  significantly  decreased  phase  II 
responses  by  76%.  This  finding  is 
supported  by  others  (Gallivan  et  al.,2000) 
where they have found that 50μg ketorolac 
decreased  phase  II  responses  by  65%  and 
150  μg  ketorolac  decreased  phase  II 
responses by 90%.  
         As  regard  to  hot  plat  test,  the  mean 
value  of  HWL  increased  from  4.7  Sec.  in 
the  control  group(S)  to  9.5  Sec.  in  K50 
group, 9.3 Sec. in K50+omeperazol group, 
and 11 Sec. in K100 group. As regard to the 
rat  tail  flick  latency,  the  mean  TFL  in 
control (S) group was 4.9 Sec., compared to 
0.7 Sec., 9.3 Sec., and 10.9 Sec. in groups 
K50,  K50+  omeperazol,  and  K100 
respectively.  This  revealed  that  ketorolac 
administrated  intrathecally  exhibited 
analgesic  effect  proved  by  increased  the 
time  of  HWL  and  TFL.  This  in  turn  is 
supported  by  other  investigators  (Eisenach 
et  al.,2002)  where  they  proved  the 
analgesic effect of ketorolac at doses of 50 
μg and 150 μg.  
         As regard to the histological changes, 
ketorolac  did  not  cause  any  pathological 
changes  in  the  spinal  cord,  such  as 
demylination, cellular infiltration, necrosis, 
or gliosis. On the  other hand, histological 
study  of  the  duodenum  revealed  mucosal 
cellular  infiltration  associated  with 
destruction of the mucous acini in animals 
of  group  K100  groups.  The  previous 
findings  resemble  the  inflammatory  effect 
of large doses of ketorolac injection, which 
could  progress  into  duodenal  ulceration. 
Gastrointestinal  side  effects  may  be  the 
limiting  factor  in  the  use  of  intrathecal 
ketorolac  for  anything  but  short  duration. 
Korkmaz  et  al.,  (2004)  reported  that 
intrathecal  ketorolac  has  not  any 
histological changes on the spinal cord,  but 
Schreiner  (1998)  reported  some  gastro-
intestinal ulceration in dogs.  
         Proton  pump  inhibitors  (omeperazol) 
bind to the proton pump parietal cells in the 
gastric  mucosa  to  inhibit  hydrogen  ions 
secretion. So, proton pump inhibitors could 
be used in healing ulcers and erosions; and 
is  used  as  prophylactic  with  NSAID  
(Conklin and Eisenach,  2003). 
Conclusion;  repeated  intrathecal  injection 
of  ketorolac  reduced  the  nociceptive 
responses  without  neuronal  histological 
changes,  but  with  minimal  gastrointestinal 
cellular  infiltration.  Ketorolac  might 
become  an  alternative  drug  in  treating 
chronic  pain  with  intrathecal  injection. 
Proton  pump  inhibitors  or  H2  antagonist 
decreased gastrointestinal side effect caused 
by ketorolac administration.  
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تيجىلىكبمربفو تيجىلىتسه تسارد 
 
 تيطع قربط –    ىبلش ىفطصم –   زببلا تمعو  
رهزلاا تعمبج بطلا تيلكب تيودلااو ريذختلاو بيجىلىتسهلا مبسقا هم -   ةرهبقلا  
 
نسٍ اشيثبح ٚطؼح ٙذيٗشيخسا شيغ ةبٖخىلاى دبعٍ ٕٚ كلاٗشخنىا ةدبٍ  ْٔقد ذْػ بي٘ق بْ
ٚم٘شىا وبذىا وخاد  , تيداشجىا ثبييَؼىا ذؼب ٌىلاا فيفخخى ةشثنب ًذخخسح ٕٚٗ  .  ذقٗ
 ةبْقىبب ثبدشقحٗ ٚينىبب ٌَسح ضاشػا ةس٘ص ٚف سبقؼيى تيبّبجىا سبثلآا طؼب جظد٘ى
تيَعٖىا  .  عبخْىا وخاد سبقؼىا ِقد ًاذخخسا ٌييقح ٚىا ثذبىا ازٕ ٚف تساسذىا جفذٕ ذقٗ
حٗ ِنسَم  ءبعيبىا ُاشئفىا ٚف ششػ ْٚثلااٗ ٚم٘شىا وبذىا جيسّ ٚيػ لىر شيثب   .  ذقٗ
 ِيب ٌّٖصٗ حٗاشخي ءبعيبىا ُاشئفىا س٘مر ٍِ ُ٘ؼبسا تساسذيى ًذخخسا 113 - 013  
ُاشئف ةششػ تػَ٘جٍ وم ٚف ثبػَ٘جٍ غبسأ ٚىإ جَسق ًاشج  ,  تػَ٘جَىا جْقد
  ٚؼيبطىا  خيَىا  ه٘يذٍ  ٍِ  شخىٗشنيٍ  ةششػ  تػشجب  ٚىٗلأا ٗ  تػَ٘جَم  جٍذخخسا
 جْقدٗ كلاٗشخنىا ةدبٍ ٍِ ًاشجٗشنيٍ ِيسَخب  تيّبثىا تػَ٘جَىا جْقدٗ تطببظ
 ٚىإ تفبظلإبب كلاٗشخنىا ةدبٍ ٍِ ًاشجٗشنيٍ ِيسَخب تثىبثىا تػَ٘جَىا 1  , 3    ًاشجييٍ
  ٍِ ًاشجٗشنيٍ تئبَب تؼباشىا تػَ٘جَىا جْقدٗ ةذؼَيى تيقا٘ىا هٗصاشبيٍٗلاا ةدبٍ ٍِ
رٗ كلاٗشخنىا  تيىبخخٍ ًبيا تؼبسا ةذَى لى .  غٍ ششػ ْٚثلاا جيسّ شثبح جئبخْىا ثشٖظا ذقٗ
 تيج٘ى٘خسٕ ثاشيغح ٙا شٖظح ٌى بَْيب ًاشجٗشنيٍ تئبَىا ضيمشخب ٓذدٗ كلاٗشخنىا ِقد
 كلاٗشخنىا سبقػ ًاذخخسا تٍلاس ٚىا تساسذىا ٓزٕ جصيخ ذقٗ ٚم٘شىا وبذىا جيسّ ٚف
ػشجىبب وَؼخسا ارإ تصبخ ٌىلأى ِنسَم  ساذجى تيقاٗ ةدبٍ ٔؼٍ وَؼخسا ٗ تبسبَْىا ت
ةذؼَىا      .                                                                                                                                                  
 